动物实验,EphA3 z-bo 2020-09-15 340

　　Recently, an international scientific team confirmed that antibodies against the protein EphA3 in the microenvironment of solid tumors have anti-tumor effects. Since EphA3 only exists in normal embryonic tissues, but is expressed in blood cancers and solid tumors, antibodies against EphA3 are suitable candidates for the treatment of solid tumors.

　　Researchers from Monash University, Ludwig Cancer Research in Australia, and KaloBios Pharmaceuticals in the US published their research results in the journal Cancer Research.

　　The team is co-led by Professor Martin Lackmann and found that even if tumor cells do not have this molecule, they can still thrive by recruiting and using cells expressing EphA3 in the tumor microenvironment.

　　Dr. Mary Vail, the first author, said: Tumor cells send signals to the surroundings and remind the surrounding cells: We (tumor cells) need blood supply and the basis for spreading. We have shown that mesenchymal stem cells expressing EphA3 are a type of cell that can promote tumor growth and angiogenesis.

　　Professor Andrew Scott’s team used mouse models of human prostate cancer to simulate human disease progression. It was found that EphA3 was found in stromal cells and blood vessels around the tumor.

　　They also observed that treating mice with an antibody against EPHA3 (chIIIA4) significantly slowed the growth of tumors. Antibodies can destroy tumor blood vessels and destroy the matrix microenvironment. As a result, cancer cells die because the "life guarantee" of the tumor is breached.

　　In addition, researchers used biopsy tumor tissues from patients with sarcoma, melanoma, prostate cancer, colon cancer, breast cancer, brain cancer, and lung cancer to confirm that stromal cells and newly formed blood vessels express EphA3. The results of this study show that the tumor microenvironment is very important, and EphA3 monoclonal antibody may be a way to target and kill a variety of solid tumors and blood cancers.